Published in Clin Cancer Res on March 26, 2012
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res (2014) 1.55
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol (2013) 1.23
The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer. PLoS One (2014) 0.98
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol (2014) 0.89
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol (2013) 0.85
Prostate cancer: beware of disseminated intravascular coagulation. BMJ Case Rep (2015) 0.81
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib. Oncol Rep (2013) 0.79
BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer. Cancer Biol Ther (2014) 0.78
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer. ACS Med Chem Lett (2015) 0.77
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer Res (2014) 0.77
Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells. ScientificWorldJournal (2013) 0.76
Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells. PLoS One (2015) 0.75
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. BMC Cancer (2016) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol (2007) 2.09
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther (2006) 1.71
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res (2010) 1.38
Adrenal androgens and intracrinology. Semin Reprod Med (2004) 1.35
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 1.28
The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am (2001) 1.24
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am (2011) 0.90
Autophagy suppresses tumorigenesis through elimination of p62. Cell (2009) 9.95
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev (2011) 7.43
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev (2013) 2.90
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol (2002) 2.03
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther (2008) 1.90
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate (2010) 1.45
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 1.41
Adult cancer survivors discuss follow-up in primary care: 'not what i want, but maybe what i need'. Ann Fam Med (2012) 1.33
Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol (2005) 1.11
Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy (2009) 1.03
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res (2006) 1.00
Inhibitory Effect of a γ-Tocopherol-Rich Mixture of Tocopherols on the Formation and Growth of LNCaP Prostate Tumors in Immunodeficient Mice. Cancers (Basel) (2011) 0.97
Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm (2006) 0.96
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs (2010) 0.95
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate (2005) 0.95
Use of hormonal therapy in men with metastatic prostate cancer. J Urol (2006) 0.92
Bone directed therapies for prostate cancer. J Urol (2007) 0.91
Obesity and prostate cancer detection: insights from three national surveys. Am J Med (2010) 0.89
A novel proteomic coculture model of prostate cancer cell growth. Proteomics (2004) 0.89
Epidemiology of Cigarette and Smokeless Tobacco Use among South Asian Immigrants in the Northeastern United States. J Oncol (2011) 0.88
A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Res (2005) 0.88
Conceptualization of disease timeline predicts posttreatment distress in breast cancer patients. Health Psychol (2004) 0.87
Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol (2004) 0.86
Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate (2013) 0.86
Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm (2006) 0.85
Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit (2012) 0.85
Ixabepilone, a new treatment option for metastatic breast cancer. Am J Clin Oncol (2010) 0.81
Tubulin-targeting agents. Cancer Chemother Biol Response Modif (2003) 0.81
Potent inhibitory effect of δ-tocopherol on prostate cancer cells cultured in vitro and grown as xenograft tumors in vivo. J Agric Food Chem (2014) 0.80
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Med Sci Monit (2003) 0.80
Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns. Am J Health Syst Pharm (2007) 0.80
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. Med Sci Monit (2003) 0.79
Tubulin-targeting agents. Cancer Chemother Biol Response Modif (2005) 0.79
Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study. Res Social Adm Pharm (2010) 0.78
An evidence-based approach to prostate cancer follow-up. Semin Oncol (2003) 0.78
Management of venous thromboembolism and the potential to impact overall survival in patients with cancer. Pharmacotherapy (2009) 0.77
Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract (2007) 0.76
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol (2005) 0.76
Hearsay medicine is not evidence-based medicine. Clin Cancer Res (2008) 0.75
Cabozantinib in prostate cancer: the beginning of a precision paradigm? J Clin Oncol (2012) 0.75
A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr (2011) 0.75
Tubulin-targeting agents. Cancer Chemother Biol Response Modif (2002) 0.75
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol (2007) 0.75
Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA). Bioorg Med Chem Lett (2009) 0.75